These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
124 related items for PubMed ID: 2937483
1. Quantification of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion in brain tissue by gas chromatography/mass spectrometry. Shih MC, Markey SP. Biomed Environ Mass Spectrom; 1986 Feb; 13(2):85-9. PubMed ID: 2937483 [Abstract] [Full Text] [Related]
2. HPLC-assay with electrochemical detection for the neurotoxin MPTP, its metabolite MPP+ and MPTP-analogues in biological samples after purification over Sephadex G10. Rollema H, Fries DS, de Vries JB, Mastebroek D, Horn AS. Life Sci; 1985 Oct 28; 37(17):1633-40. PubMed ID: 3877232 [Abstract] [Full Text] [Related]
3. Peripheral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its main metabolite 1-methyl-4-phenylpyridinium ion (MPP+) in the rat. Algeri S, Ambrosio S, Garofalo P, Gerli P. Eur J Pharmacol; 1987 Sep 11; 141(2):309-12. PubMed ID: 3500067 [Abstract] [Full Text] [Related]
4. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. Mizuno Y, Sone N, Saitoh T. J Neurochem; 1987 Jun 11; 48(6):1787-93. PubMed ID: 3106573 [Abstract] [Full Text] [Related]
5. 4-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP+ concentrations and neurotoxicity. Irwin I, Langston JW, DeLanney LE. Life Sci; 1987 Feb 23; 40(8):731-40. PubMed ID: 3492652 [Abstract] [Full Text] [Related]
6. Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Ransom BR, Kunis DM, Irwin I, Langston JW. Neurosci Lett; 1987 Apr 10; 75(3):323-8. PubMed ID: 3495754 [Abstract] [Full Text] [Related]
9. 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Langston JW, Irwin I, Langston EB, Forno LS. Neurosci Lett; 1984 Jul 13; 48(1):87-92. PubMed ID: 6332288 [Abstract] [Full Text] [Related]
13. Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, to neuromelanin. D'Amato RJ, Benham DF, Snyder SH. J Neurochem; 1987 Feb 13; 48(2):653-8. PubMed ID: 3491879 [Abstract] [Full Text] [Related]
14. Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse. Perry TL, Yong VW, Jones K, Wall RA, Clavier RM, Foulks JG, Wright JM. Neurosci Lett; 1985 Aug 05; 58(3):321-6. PubMed ID: 3876525 [Abstract] [Full Text] [Related]
15. Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity? Irwin I, Langston JW. Life Sci; 1985 Jan 21; 36(3):207-12. PubMed ID: 3871240 [Abstract] [Full Text] [Related]
16. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. Vyas I, Heikkila RE, Nicklas WJ. J Neurochem; 1986 May 21; 46(5):1501-7. PubMed ID: 3485701 [Abstract] [Full Text] [Related]
18. Uptake of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and the N-methyl-4-phenylpyridinium ion (MPP+) into fetal mouse brain through the placenta. Ohya Y, Naoi M, Ochi N, Mizutani N, Watanabe K, Nagatsu T. Neurosci Lett; 1989 Oct 23; 105(1-2):221-6. PubMed ID: 2485882 [Abstract] [Full Text] [Related]